? In 2011 and 2015, Aier Ophthalmology successively established "Aier Optometry Research Institute" and "Aier Ophthalmology Research Institute". By now, Aier Ophthalmology has opened up three major fields of ophthalmology: medicine, academia and research. The establishment of the Academy and the Research Institute will significantly improve the scientific research and clinical level of Aier Ophthalmology, and in this way, push forward the development and progress of ophthalmology medical care in China. As of 2016, the team of professional ophthalmologists and doctors belonging to Aier Ophthalmology has reached nearly 3,000, including a large number of master's degree supervisors, doctoral supervisors, PhDs, post-doctoral students, scholars studying in Europe and the United States, as well as clinically experienced core specialists, which is a high-profile force in China's ophthalmology field.
?On July 9, 2014, World Bank President Jim Yong Kim visited Aier Ophthalmology Changsha Hospital and promoted Aier Ophthalmology's unique sustainable public welfare charity model in developing countries around the world. 2015, Aier Ophthalmology acquired the Hong Kong Asia Medical Group, opening the pace of Aier Ophthalmology's internationalization, and 2017, Aier Ophthalmology acquired the well-known eye center in the United States, the pace of internationalization is next. In 2017, Aier Ophthalmology acquired a well-known eye center in the United States, the pace of internationalization is another city. The development and growth of Aier Ophthalmology has always been based on the mission of "enabling all people, rich or poor, to enjoy the right to eye health", pursuing the harmonious unity of social responsibility and its own development, and providing more high-quality ophthalmic medical services for patients through the pioneering "cross-subsidization" model. Through the pioneering "cross-subsidization" model, we provide patients with higher-quality ophthalmic medical services on the one hand, and at the same time, comprehensively carry out the prevention and treatment of blindness, devote ourselves to public welfare and help the disadvantaged groups, and join hands with all sectors of the society to promote the comprehensive development of the cause of preventing blindness in China. The company's mission is to promote the comprehensive development of the prevention of blindness in China.
? II. The company's scope of business: investment in ophthalmic hospitals and hospital management services, (shall not be engaged in the absorption of deposits, fund-raising collection, entrusted loans, the issuance of notes, the issuance of loans and other state financial supervision and financial credit business). Ophthalmology medical technology research, telemedicine software research and development, production, sales; ophthalmology, internal medicine, anesthesiology, laboratory, film and television imaging, optometry (projects subject to approval by law, approved by the relevant departments before carrying out business activities).
? III. Basic information of the company ：
IV. Information on the Company's Issuance:
V. Analysis of the Company's Main Composition
VI. Company news announcement : 2017 annual report will be disclosed on 2018-04-21, it is expected that the net profit attributable to shareholders of the listed company in January-December 2017 profit of 724.774 million yuan-752.5807 million yuan, an increase of 30%-35% over the previous year. The net profit of the Company in this reporting period increased by 30%-35% year-on-year, mainly due to the following reasons: on the one hand, the operating scale of the Company has been expanding continuously, the outpatient volume and operation volume of various hospitals have been increasing rapidly, and the internationalization strategy has been implemented smoothly; on the other hand, due to the continuous enhancement of the influence of the Company's brand, the market share of various businesses has been increasing year-on-year, and the operational efficiency and operating effectiveness have been further improved, which ensured a sustained growth of the Company's operating revenue and net profit in the reporting period. On the other hand, as the company's brand influence continues to strengthen, the market share of various businesses is increasing year by year, the operational efficiency and operational effectiveness has been further improved, to ensure that the company's operating income and net profit in the reporting period continued to grow.
? VII. Company Events
VIII. Industry Analysis
The preliminary investigation of the background of Aier Ophthalmology is completed!